Equities analysts expect that Illumina, Inc. (NASDAQ:ILMN) will report earnings of $1.25 per share for the current quarter, Zacks reports. Six analysts have made estimates for Illumina’s earnings, with estimates ranging from $1.17 to $1.40. Illumina reported earnings of $1.11 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 12.6%. The firm is expected to report its next quarterly earnings report after the market closes on Tuesday, October 23rd.

On average, analysts expect that Illumina will report full year earnings of $5.46 per share for the current fiscal year, with EPS estimates ranging from $5.39 to $5.79. For the next fiscal year, analysts forecast that the business will post earnings of $6.17 per share, with EPS estimates ranging from $5.70 to $6.79. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Illumina.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same quarter last year, the business posted $0.82 earnings per share. The business’s revenue for the quarter was up 25.4% on a year-over-year basis.

A number of brokerages have recently weighed in on ILMN. Zacks Investment Research cut Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub cut Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank increased their price objective on Illumina to $350.00 and gave the company a “buy” rating in a research note on Friday, October 12th. ValuEngine lowered Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Finally, UBS Group assumed coverage on Illumina in a research note on Tuesday, October 9th. They set a “neutral” rating and a $340.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company. Illumina currently has an average rating of “Buy” and an average target price of $324.76.

In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $321.58, for a total value of $1,061,214.00. Following the sale, the director now directly owns 385,604 shares of the company’s stock, valued at approximately $124,002,534.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $331.39, for a total value of $3,313,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,483 shares of company stock worth $17,702,063. Corporate insiders own 0.54% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Jennison Associates LLC boosted its stake in Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after buying an additional 185,745 shares during the last quarter. Fred Alger Management Inc. boosted its stake in Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after buying an additional 137,302 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Illumina by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock worth $168,863,000 after buying an additional 31,985 shares during the last quarter. Millennium Management LLC boosted its stake in Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock worth $153,318,000 after buying an additional 377,283 shares during the last quarter. Finally, Federated Investors Inc. PA boosted its stake in Illumina by 4.1% in the 2nd quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock worth $143,167,000 after buying an additional 20,324 shares during the last quarter. 89.91% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ILMN stock traded down $8.35 during mid-day trading on Monday, reaching $313.10. The stock had a trading volume of 1,482,906 shares, compared to its average volume of 1,087,215. Illumina has a 12-month low of $198.21 and a 12-month high of $372.61. The stock has a market cap of $47.25 billion, a P/E ratio of 78.28, a P/E/G ratio of 2.66 and a beta of 0.97. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.